Last reviewed · How we verify
NCT05812027
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
trial testing Tumor and HLA Profiling in Head and Neck Cancer in 1,150 participants. Participants enrolled and being followed up; not accepting new ones.
1 January 2026
Quick facts
| Lead sponsor | TScan Therapeutics, Inc. |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,150 |
| Start date | 26 June 2023 |
| Primary completion | 1 January 2026 |
| Estimated completion | 14 January 2027 |
| Sites | 21 locations across United States |
Drugs / interventions tested
- Tumor and HLA Profiling
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Cervical Cancer — all drugs for Cervical Cancer →
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
- HPV16 Related Cancers — all drugs for HPV16 Related Cancers →
Sponsor
TScan Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Head and Neck Cancer or Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05812027
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other TScan Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05973487 — A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metasta · Phase 1 · active not recruiting
- NCT05230186 — A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive · unknown
- NCT04680416 — Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors · withdrawn
- NCT04397900 — Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05812027 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TScan Therapeutics, Inc.
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05812027.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing